Trevi Therapeutics, Inc. TRVI
14.41
(0.27)
(1.84%)
as of 25 Sep
- Market cap
- $2.1B
- P/E
- 0.0×
Follow TRVI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
37.28 | 24.75 | 19.66 | 21.93 |
+8 more quarters Free account |
Net Debt/EBITDA |
15.57 | 11.55 | 18.48 | 14.05 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 1.27 | 0.92 | 0.92 | |
Capex/Depreciation |
(3.65) | (3.00) | 0.00 | (0.32) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.11) | (0.12) | (0.06) | (0.08) | |
Cash per Share |
2.04 | 1.18 | 1.40 | 1.34 | |
Shareholders Equity per Share |
2.05 | 1.18 | 1.36 | 1.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.05 | 1.18 | 1.36 | 1.31 | |
Free Cash Flow |
(17.55) | (16.79) | (7.63) | (10.89) | |
Working Capital |
316.97 | 169.01 | 181.91 | 189.26 | |
Capital Expenditures |
(0.12) | (0.10) | 0.00 | (0.01) | |
Net Current Asset Value |
316.69 | 168.64 | 181.46 | 188.73 | |
| Other line items | |||||
Quick Ratio |
36.50 | 24.14 | 19.31 | 21.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.11) | (0.06) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.04 | 1.82 | 3.66 | 2.16 | |
Average Assets |
269.43 | 143.31 | 152.17 | 134.13 | |
Average Common Equity |
260.00 | 135.79 | 141.44 | 124.38 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates